E-drug: Science vs Shareholders
---------------------------------------------
In researching a series about Big Pharma, and in particular looking
at the on-going battle between science and investors, a very worrying
trend seems to be emerging. A company stumbles across a drug that
could treat/cure a condition that only exists in the poorest corners
of the Third World. But instead of seeing the new drug as a possible
miracle of modern science, the company's Board sees it as a business
dilemma --- a potential public relations disaster for the company and
a huge profit drain to the shareholders. Accordingly, they order the
R&D stopped at the earliest stage, before anybody finds out about it.
In light of what's been going on in South Africa, do any e-druggers
know of similar and documentable science vs shareholders stories?
Alan Train
journalist
alantrain@post.com
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.